GERN
Geron Corporation NASDAQ Listed Jul 31, 1996$1.41
+2.55%
vs $1.37
Mkt Cap $901.3M
52w Low $1.04
37.6% of range
52w High $2.01
50d MA $1.36
200d MA $1.39
P/E (TTM)
—
EV/EBITDA
—
P/B
4.2x
Debt/Equity
1.1x
ROE
-37.0%
P/FCF
-8.2x
RSI (14)
69.00
ATR (14)
$0.08
Beta
0.67
50d MA
$1.36
200d MA
$1.39
Avg Volume
13.1M
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
919 East Hillsdale Boulevard · Foster City, CA 94404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | -0.03 | -0.03 | +0.0% | 1.72 | +0.0% | -4.1% | +1.8% | -7.7% | -7.1% | +2.1% | — |
| Nov 5, 2025 | BMO | -0.04 | -0.03 | +18.3% | 1.09 | -1.8% | -0.9% | -0.9% | +8.4% | +7.8% | -0.8% | — |
| Aug 6, 2025 | BMO | -0.03 | -0.02 | +33.3% | 1.39 | +2.2% | -6.5% | -1.5% | +6.2% | -0.7% | +5.9% | — |
| May 7, 2025 | BMO | -0.04 | -0.03 | +25.0% | 1.31 | -0.8% | -3.8% | -6.3% | +8.5% | -6.2% | -0.8% | — |
| Feb 26, 2025 | BMO | -0.04 | -0.04 | +0.0% | 1.61 | -0.6% | +8.1% | +1.1% | -2.8% | -2.9% | +1.2% | — |
| Nov 7, 2024 | BMO | -0.09 | -0.04 | +55.6% | 4.29 | -1.9% | -0.9% | -3.1% | -3.6% | -2.5% | -4.1% | — |
| Aug 8, 2024 | BMO | -0.11 | -0.10 | +9.1% | 4.60 | +0.0% | +2.2% | +0.6% | -3.4% | -2.8% | +0.5% | — |
| May 2, 2024 | BMO | -0.10 | -0.09 | +10.0% | 3.95 | +1.3% | -0.5% | -5.1% | +3.8% | -1.6% | +1.8% | — |
| Feb 28, 2024 | BMO | -0.10 | -0.09 | +10.0% | 1.95 | +3.6% | +2.6% | +13.0% | -8.0% | +0.5% | +0.5% | — |
| Nov 2, 2023 | BMO | -0.10 | -0.08 | +20.0% | 1.78 | -1.1% | +11.2% | -6.6% | +3.2% | -3.1% | -5.4% | — |
| Aug 3, 2023 | BMO | -0.08 | -0.09 | -12.5% | 3.16 | -3.8% | -6.3% | -1.4% | +1.4% | +2.0% | -0.3% | — |
| May 11, 2023 | BMO | -0.09 | -0.07 | +22.2% | 2.89 | +2.1% | +7.3% | -1.9% | -1.6% | +1.0% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 5 | Needham | Maintains | Buy → Buy | — | $1.15 | $1.10 | -4.3% | -5.2% | -0.9% | -0.9% | +8.4% | +7.8% |
| May 8 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $1.31 | $1.30 | -0.8% | -3.8% | -6.3% | +8.5% | -6.2% | -0.8% |
| Mar 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.60 | $1.62 | +1.2% | +10.6% | -5.6% | -1.8% | +6.1% | -0.6% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $1.60 | $1.62 | +1.2% | +10.6% | -5.6% | -1.8% | +6.1% | -0.6% |
| Feb 27 | Stifel | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | +8.1% | +1.1% | -2.8% | -2.9% | +1.2% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | +8.1% | +1.1% | -2.8% | -2.9% | +1.2% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $1.61 | $1.60 | -0.6% | +8.1% | +1.1% | -2.8% | -2.9% | +1.2% |
| Feb 27 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.61 | $1.60 | -0.6% | +8.1% | +1.1% | -2.8% | -2.9% | +1.2% |
| Feb 26 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.37 | $1.73 | -27.0% | -32.1% | +8.1% | +1.1% | -2.8% | -2.9% |
| Feb 18 | B. Riley Securities | Maintains | Buy → Buy | — | $2.56 | $2.54 | -0.8% | +2.7% | -3.4% | +3.5% | -2.3% | -7.0% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $3.17 | $3.10 | -2.2% | -6.0% | -1.3% | +2.4% | -3.0% | -1.0% |
| Dec 13 | Needham | Maintains | Buy → Buy | — | $3.92 | $3.98 | +1.5% | -1.5% | -1.3% | +3.1% | -4.1% | -2.9% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.98 | $3.98 | +0.0% | +0.3% | -0.3% | -1.5% | -1.5% | -1.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.22 | $4.35 | +3.1% | +1.2% | +0.5% | -0.9% | -3.1% | -3.6% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $4.60 | $4.60 | +0.0% | +2.2% | +0.6% | -3.4% | -2.8% | +0.5% |
| Jul 26 | Needham | Maintains | Buy → Buy | — | $4.29 | $4.35 | +1.4% | +8.6% | +0.6% | +0.0% | +1.1% | +0.8% |
| Jun 10 | Stifel | Maintains | Buy → Buy | — | $4.59 | $4.58 | -0.2% | +9.8% | +1.0% | +0.0% | -4.1% | -0.2% |
| Jun 7 | Needham | Maintains | Buy → Buy | — | $3.89 | $4.46 | +14.7% | +18.0% | +9.8% | +1.0% | +0.0% | -4.1% |
| Jun 7 | Wedbush | Maintains | Outperform → Outperform | — | $3.89 | $4.46 | +14.7% | +18.0% | +9.8% | +1.0% | +0.0% | -4.1% |
| May 2 | Needham | Maintains | Buy → Buy | — | $4.08 | $4.14 | +1.5% | -3.2% | -0.5% | -5.1% | +3.8% | -1.6% |
| Apr 30 | Baird | Downgrade | Outperform → Neutral | — | $4.14 | $4.02 | -2.9% | -5.1% | +3.8% | -3.2% | -0.5% | -5.1% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $3.44 | $3.45 | +0.3% | +9.6% | -3.4% | -5.2% | +3.8% | +2.8% |
| Apr 10 | Wedbush | Maintains | Outperform → Outperform | — | $3.43 | $3.34 | -2.6% | +0.3% | +9.6% | -3.4% | -5.2% | +3.8% |
| Mar 15 | Goldman Sachs | Maintains | Buy → Buy | — | $1.75 | $3.00 | +71.4% | +92.0% | -5.4% | +2.5% | +5.5% | -3.2% |
| Mar 15 | Wedbush | Maintains | Outperform → Outperform | — | $1.75 | $3.00 | +71.4% | +92.0% | -5.4% | +2.5% | +5.5% | -3.2% |
| Mar 15 | Needham | Maintains | Buy → Buy | — | $1.75 | $3.00 | +71.4% | +92.0% | -5.4% | +2.5% | +5.5% | -3.2% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $1.88 | $1.83 | -2.7% | -6.9% | +92.0% | -5.4% | +2.5% | +5.5% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $2.14 | $1.93 | -9.8% | -12.1% | -6.9% | +92.0% | -5.4% | +2.5% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $2.26 | $2.26 | +0.0% | -8.0% | +0.5% | +0.5% | +0.0% | +7.1% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $2.07 | $2.10 | +1.4% | -5.8% | +2.6% | +13.0% | -8.0% | +0.5% |
| Sep 12 | Goldman Sachs | Upgrade | Neutral → Buy | — | $2.34 | $2.59 | +10.7% | -1.7% | -2.2% | +2.2% | -3.9% | -0.9% |
| Aug 29 | Wedbush | Maintains | Outperform → Outperform | — | $2.44 | $2.30 | -5.7% | -5.7% | +3.5% | +2.1% | +2.1% | -1.6% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $3.16 | $3.04 | -3.8% | -6.3% | -1.4% | +1.4% | +2.0% | -0.3% |
| Jun 15 | Needham | Maintains | Buy → Buy | — | $3.09 | $3.12 | +1.0% | -1.9% | -1.0% | +5.0% | +2.2% | -3.1% |
| Jun 5 | Needham | Maintains | Buy → Buy | — | $3.60 | $3.65 | +1.4% | +0.6% | -0.6% | -1.1% | +3.7% | -2.4% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $2.89 | $2.95 | +2.1% | +7.3% | -1.9% | -1.6% | +1.0% | -1.3% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $2.51 | $2.58 | +2.8% | +6.4% | -0.7% | -8.7% | +0.4% | -2.1% |
| Mar 28 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.34 | $2.31 | -1.3% | -7.3% | +2.8% | -4.0% | +1.4% | +0.0% |
| Mar 20 | B. Riley Securities | Maintains | Buy → Buy | — | $2.53 | $2.53 | +0.0% | -2.8% | -4.9% | -1.7% | -0.9% | +2.2% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $2.65 | $2.62 | -1.1% | -4.5% | -2.8% | -4.9% | -1.7% | -0.9% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $2.65 | $2.62 | -1.1% | -4.5% | -2.8% | -4.9% | -1.7% | -0.9% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $2.50 | $2.53 | +1.2% | +18.0% | +11.9% | +0.0% | -2.4% | -1.9% |
| Jan 4 | Wedbush | Maintains | Outperform → Outperform | — | $2.40 | $3.41 | +42.1% | +32.9% | -22.3% | +0.8% | +18.0% | +11.9% |
| Oct 28 | Wedbush | Maintains | Outperform → Outperform | — | $2.30 | $2.38 | +3.5% | +4.8% | -7.9% | -3.2% | +0.0% | -5.6% |
| Aug 22 | Needham | Maintains | Buy → Buy | — | $2.23 | $2.23 | +0.0% | -2.2% | +10.1% | -2.1% | +1.3% | +0.4% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $2.05 | $2.18 | +6.3% | +14.6% | +0.9% | -6.3% | -3.2% | +1.9% |
| May 10 | Needham | Maintains | Buy → Buy | — | $1.23 | $1.33 | +8.1% | +20.3% | -6.1% | +2.9% | +1.4% | -2.8% |
| Nov 2 | Baird | Maintains | Outperform → Outperform | — | $1.57 | $1.63 | +3.8% | +3.2% | +2.5% | +0.0% | -0.6% | +4.2% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.95 | +10.8% | +4.0% | +3.3% | +2.1% | +6.2% | -5.4% |
| Aug 3 | Stifel | Maintains | Buy → Buy | — | $1.59 | $1.73 | +8.8% | +11.3% | -2.3% | -0.6% | -3.5% | +1.2% |
No insider trades available.
8-K
Geron Corporation -- 8-K Filing
Geron Corporation held its 2026 Annual Meeting on March 26, 2026, with stockholders voting on multiple proposals, though specific voting outcomes and proposal details are not disclosed in this summary.
May 27
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K
Geron Corp -- 8-K Filing
Geron Corporation reported Q4 2025 and full-year 2025 financial results, highlighting business progress as it continues advancing its blood cancer treatment pipeline.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Soleus Capital Management, L.p. | 41,508,659 | $62M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 26,669,029 | $40M | New | Mar 2026 |
| 3 | Morgan Stanley | 25,206,836 | $33M | Added | Dec 2025 |
| 4 | Citadel Advisors Llc | 21,576,569 | $32M | Added | Mar 2026 |
| 5 | Point72 Asset Management | 20,457,134 | $30M | New | Mar 2026 |
| 6 | Clearbridge Investments, Llc | 19,620,320 | $29M | Added | Mar 2026 |
| 7 | Vivo Capital, Llc | 8,671,797 | $13M | New | Mar 2026 |
| 8 | Millennium Management | 7,321,522 | $11M | Added | Mar 2026 |
| 9 | Fmr Llc | 6,597,156 | $10M | Reduced | Mar 2026 |
| 10 | Northern Trust Corp | 4,862,264 | $7M | Added | Mar 2026 |
| 11 | Segall Bryant & Hamill, Llc | 4,740,048 | $7M | New | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 4,668,783 | $7M | New | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 4,556,278 | $7M | Added | Mar 2026 |
| 14 | Ubs Group Ag | 3,693,333 | $6M | Added | Mar 2026 |
| 15 | Marshall Wace, Llp | 2,960,047 | $4M | New | Mar 2026 |
| 16 | Nuveen, Llc | 2,931,489 | $4M | Added | Mar 2026 |
| 17 | Candriam S.c.a. | 2,839,484 | $4M | Reduced | Dec 2025 |
| 18 | Janus Henderson Group Plc | 2,218,196 | $3M | New | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 1,889,468 | $3M | Reduced | Mar 2026 |
| 20 | Renaissance Technologies Llc | 1,799,521 | $3M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$901.3M
Enterprise Value
$785.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.20x
P/B
4.15x
P/S
4.78x
P/FCF
-8.22x
EV/EBITDA
—
Shares Out
666.7M
Financials (TTM)
Revenue
$196.1M
Net Income
-$69.6M
EBITDA
-$36.9M
Free Cash Flow
-$111.1M
Op Cash Flow
-$111.0M
EPS Basic
$-0.13
EPS Diluted
$-0.10
EPS Forward
$-0.04
Gross Margin
86.6%
Op Margin
-19.1%
Net Margin
-35.5%
Balance Sheet
Total Assets
$570.5M
Total Liab.
$344.7M
Total Equity
$225.9M
Cash
$359.8M
LT Debt
$231.7M
Book Value/Sh
$0.34
Debt/Equity
1.11x
Current Ratio
4.66
Quick Ratio
4.66
Returns & Growth
ROE
-37.0%
ROA
-14.6%
ROIC
-11.2%
Rev Growth YoY
+138.8%
EPS Growth YoY
+51.8%
Price Returns
2W
-10.7%
1M
-18.8%
3M
-25.6%
6M
+5.9%
12M
-17.8%
Technicals
52W High
$2.01
52W Low
$1.04
50d MA
$1.36
200d MA
$1.39
RSI (14)
69.00
ATR (14)
$0.08
Beta
0.67
Avg Volume
13.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.89
High
$8.00
Low
$4.00
Median
$6.00
Data updated apr 25, 2026 11:13am
· Source: financialmodelingprep.com